摘要
目的研究三草方(Sancaofang,SCF)不同组分及其配伍体内外抗肺癌的作用,筛选出有效的抗癌组分并确定最合适的配伍方案,探索SCF抗肺癌的物质基础。方法采用不同体积分数乙醇提取,经大孔树脂纯化得黄酮类(D)、萜类(E)及其他类组分(A+B+C);体外实验采用两种人肺癌细胞株SPC-A-1和A549,以MTT法测定不同组分及其配伍对细胞增殖活性的影响;体内实验采用接种Lewis肺癌细胞的C57BL/6J小黑鼠,作为药效的动物模型,以抑瘤率、脾指数、胸腺指数为指标进行药效评价。结果SCF黄酮类、萜类组分对两种细胞有较强的抑制作用,组分EⅠ、DⅡ及EⅡ对SPC-A-1细胞的IC50分别为生药量6.35、7.71、6.75mg/mL,对A549细胞的IC50分别为生药量8.05、6.79、6.88mg/mL;黄酮类和萜类组分配伍(DⅠ+DⅡ+EⅠ+EⅡ)对Lewis小鼠肿瘤生长具有抑制作用,且可提高荷瘤小鼠的胸腺指数。体内外实验结果表明,黄酮类、萜类组分配伍后具有明显的协同抑瘤活性。结论SCF黄酮类、萜类组分间的配伍为最佳配伍,SCF有效组分具有良好的抗肺癌应用前景。
Objective To study the in vivo and in vitro anti-lung cancer activity of Sancaofang （SCF） components and their compatibility, screen the most effective components of anti-tumor, ascertain the best suitable compatibility program, and research the anti-tumor material base of SCF. Methods Alcohol parts （95% and 60%） were prepared and SCF components were separated by maeroporous resin; SPC-A-1 and A549 cell models were adopted for in vitro experiment and MTT assay was used; C57 BL/6J black mice injected with Lewis cells were adopted for the in vivo experiment; and tumor inhibition ratio, spleen index, and thymus index were used for the evaluation. Results Components EI , DH , and En had comparative strong anti-tumor activity against SPC-A-1 and A549 cells and IC50 was relatively low; The in vivo and in vitro experiments showed that component compatibility of D and E had the apparent synergism anti-tumor activity. Conclusion The most suitable compatibility program is the compatibility of component D and E, the components of SCF will have prospect application to anti-tumor.
出处
《中草药》
CAS
CSCD
北大核心
2010年第4期592-596,共5页
Chinese Traditional and Herbal Drugs
基金
江苏省中医药领军人才项目(2006)
江苏省自然科学基金资助项目(BK2006155)
